title: Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
abstract: OBJECTIVE
  A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL).
  
  
  METHODS
  Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695).
  
  
  RESULTS
  Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%).
  
  
  CONCLUSIONS
  Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
authors: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
authors: Hui-Jen
authors: HJ
authors: Tsai
authors: Sheng-Fung
authors: SF
authors: Lin
authors: Chu-Chih
authors: CC
authors: Chen
authors: Tsai-Yun
authors: TY
authors: Chen
authors: Wu-Chou
authors: WC
authors: Su
authors: Wen-Li
authors: WL
authors: Hwang
authors: Jin-Ching
authors: JC
authors: Lin
authors: Tzeon-Jye
authors: TJ
authors: Chiou
authors: Weio-Yau
authors: WY
authors: Kao
authors: Chang-Fang
authors: CF
authors: Chiu
authors: Yi-Fang
authors: YF
authors: Chang
authors: Jeffrey S
authors: JS
authors: Chang
authors: Ming-Chih
authors: MC
authors: Chang
authors: Ih-Jen
authors: IJ
authors: Su
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D059248:Chemoradiotherapy / Q000009:adverse effects; D003131:Combined Modality Therapy; D060830:Consolidation Chemotherapy; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D055815:Young Adult
keywords: concurrent chemoradiotherapy; localized; nasal natural killer/T-cell lymphoma